Advertisement


Robert Olson, MD, on Quality-of-Life Outcomes After Stereotactic Ablative Radiotherapy vs Standard-of-Care Palliative Treatments

2019 ASTRO Annual Meeting

Advertisement

Robert Olson, MD, of the BC Cancer Centre for the North, discusses a secondary analysis of the SABR-COMET trial, which showed there was a small magnitude decline in quality of life in both arms of the study but no associated detriment with stereotactic ablative radiotherapy (Abstract 148).



Related Videos

Head and Neck Cancer

Sue Sun Yom, MD, PhD, on Oropharyngeal Cancer: Deintensifying Radiation Therapy Plus Chemotherapy

Sue Sun Yom, MD, PhD, of the University of California, San Francisco, discusses phase II results showing that swallowing-related quality of life after deintensified chemoradi...

CNS Cancers

Erica H. Bell, PhD, on Low-Grade Gliomas: Subgroup Analysis of the NRG Oncology/RTOG 9802 Trial

Erica H. Bell, PhD, of The Ohio State University, discusses phase III findings from a prognostic and predictive molecular subgroup analysis of radiotherapy vs radiotherapy pl...

Gastroesophageal Cancer

Steven H. Lin, MD, PhD, on Esophageal Cancer: Proton Beam vs Intensity-Modulated Radiation Therapy

Steven H. Lin, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase II findings that showed proton beam therapy improved total toxicity burden score...

Lung Cancer
Immunotherapy

Andreas Rimner, MD, on the PACIFIC Trial: Durvalumab for Stage III NSCLC

Andreas Rimner, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings showing that, for patients with stage III non–small cell lung cancer, durvalumab reduc...

Prostate Cancer

Ryan Phillips, MD, PhD, on Oligometastatic Prostate Cancer: ORIOLE Trial on Observation vs Stereotactic Ablative Radiation

Ryan Phillips, MD, PhD, of Johns Hopkins Medical Institutions, discusses phase II findings suggesting that treatment with stereotactic ablative radiation significantly decrea...

Advertisement

Advertisement



Advertisement